Crestwood Advisors Group LLC Has $633,000 Stock Position in Bristol Myers Squibb Company $BMY

Crestwood Advisors Group LLC lessened its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 12.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,666 shares of the biopharmaceutical company’s stock after selling 1,917 shares during the period. Crestwood Advisors Group LLC’s holdings in Bristol Myers Squibb were worth $633,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. New England Asset Management Inc. boosted its stake in shares of Bristol Myers Squibb by 0.8% in the 1st quarter. New England Asset Management Inc. now owns 39,476 shares of the biopharmaceutical company’s stock worth $2,408,000 after buying an additional 305 shares during the last quarter. Commonwealth Equity Services LLC lifted its holdings in Bristol Myers Squibb by 1.1% during the first quarter. Commonwealth Equity Services LLC now owns 1,288,407 shares of the biopharmaceutical company’s stock worth $78,580,000 after acquiring an additional 13,959 shares during the period. Sage Capital Advisors llc lifted its holdings in Bristol Myers Squibb by 60.7% during the second quarter. Sage Capital Advisors llc now owns 85,234 shares of the biopharmaceutical company’s stock worth $3,946,000 after acquiring an additional 32,181 shares during the period. Advocate Group LLC boosted its position in Bristol Myers Squibb by 4.8% in the second quarter. Advocate Group LLC now owns 154,239 shares of the biopharmaceutical company’s stock worth $7,140,000 after purchasing an additional 7,088 shares during the last quarter. Finally, Castle Rock Wealth Management LLC grew its stake in Bristol Myers Squibb by 458.2% in the 2nd quarter. Castle Rock Wealth Management LLC now owns 44,559 shares of the biopharmaceutical company’s stock valued at $2,088,000 after purchasing an additional 36,576 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president directly owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.07% of the company’s stock.

Bristol Myers Squibb Stock Up 0.5%

BMY opened at $46.70 on Friday. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33. The company has a market cap of $95.07 billion, a PE ratio of 18.83, a price-to-earnings-growth ratio of 2.23 and a beta of 0.33. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The company has a 50 day moving average of $45.26 and a 200 day moving average of $46.73.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.11. The firm had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business’s quarterly revenue was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were given a dividend of $0.62 per share. The ex-dividend date was Friday, October 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.3%. Bristol Myers Squibb’s dividend payout ratio is currently 83.78%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BMY shares. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, October 13th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a research note on Tuesday, August 5th. Finally, Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fifteen have assigned a Hold rating to the stock. According to MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and an average target price of $57.23.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.